Saniona secures SEK 87 million ($10 million) non-dilutive term loan
Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that it has entered into a non-dilutive term loan agreement for SEK 87 million ($10 million)withFormue Nord Fokus A/S. Proceeds from the loan will be used to support Saniona’s clinical development programs and for general working capital purposes.
Rami Levin, President & Chief Executive Officer of Saniona, commented, “We just initiated a Phase 1 trial of SAN711, and we are preparing to initiate two Phase 2b trials with Tesomet in Prader-Willi syndrome and hypothalamic obesity, respectively. At the same time, we are already looking ahead and have identified ways to speed up the conduct of these trials and enable a smooth and quick transition to the next phase of clinical development. These initiatives will require additional capital; thus we secured this loan, which provides non-dilutive funding on competitive terms. The loan allows us to support these initiatives without impacting share capital.”
There are no warrants or equity conversion features associated with the loan, other than conversion eligibility in the event of default. A 6% commitment fee will be paid to Formue Nord, resulting in SEK 81.78 million in net proceeds to the company. The loan will accrue interest at 1% on the gross amount of the loan per beginning 30-day period until the loan is repaid and settled. The loan matures in June 2023.
Rasmus Viggers, Chief Investment Officer and Partner at Formue Nord, commented, “We continue to see strong potential for value creation in Saniona’s strategy to advance innovative medicines for rare diseases. We are pleased to support this mission and we are confident in the company’s ability to deliver.”
For more information, please contact
Trista Morrison, Chief Communications Officer, Saniona. Office: + 1 (781) 810-9227. Email: firstname.lastname@example.org
The information was submitted for publication, through the agency of the contact person set out above, at 14.00 CEST on 14July2021.
Saniona is a biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for rare disease patients around the world. The company’s lead product candidate, Tesomet, is in mid-stage clinical trials for hypothalamic obesity and Prader-Willi syndrome, severe rare disorders characterized by uncontrollable hunger and intractable weight gain. Saniona’s robust drug discovery engine has generated a library now consisting of more than 20,000 proprietary modulators of ion channels, a significantly untapped drug class that is scientifically validated. Lead candidate SAN711 is in a Phase 1 clinical trial and may be applicable in the treatment of rare neuropathic disorders, with SAN903 for rare inflammatory and fibrotic disorders advancing through preclinical development. Led by an experienced scientific and operational team, Saniona has an established research organization in Copenhagen, Denmark and a corporate office in the Boston, Massachusetts area, U.S. The company’s shares are listed on Nasdaq Stockholm Small Cap (OMX: SANION). Read more at www.saniona.com.
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Nikkiso Cryogenic Services Recommissioned Air Separation Plant in India for Critical Oxygen Supply28.7.2021 02:30:00 CEST | Press release
TEMECULA, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- Nikkiso Cryogenic Industries’ Clean Energy & Industrial Gases Group (Group), a subsidiary of Nikkiso Co., Ltd (Japan), is proud to announce they have completed the recommissioning of an Air Separation plant in Patancheru, Hyderabad India. This project was done in coordination with the Telangana government (TEL), and Greenko Foundation (GKO). Due to the ongoing pandemic crisis in India, the Indian government initiated a directive to restart the operation and LOX production to meet the urgent demands for medical oxygen. GKO has taken the old shut-down Oxygen plant on rental basis from Air Water India Private Limited (AWI) for period of (2) two years. In May 2021, the Group partnered along with GKO in recommissioning of the plant. Nikkiso Cryogenic Services provided critical technical support and spare parts, including nozzle actuators and vibration components, and Nikkiso Cosmodyne India Pvt. Ltd. provided field service support. Critica
Invitation to DNO Q2 2021 Earnings Call28.7.2021 00:31:28 CEST | Press release
Oslo, 28 July 2021 – DNO ASA, the Norwegian oil and gas operator, will publish its Q2 2021 operating and interim financial results on 29 July 2021 at 07:00 (CEST). A videoconference call with executive management will follow at 15:00 (CEST). Please visit www.dno.no for login details. – For further information, please contact: Media: email@example.com Investors: firstname.lastname@example.org – DNO ASA is a Norwegian oil and gas operator focused on the Middle East and the North Sea. Founded in 1971 and listed on the Oslo Stock Exchange, the Company holds stakes in onshore and offshore licenses at various stages of exploration, development and production in the Kurdistan region of Iraq, Norway, United Kingdom, Netherlands, Ireland and Yemen. – This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Synchronoss Names Christina Gabrys Chief Legal Officer27.7.2021 22:05:00 CEST | Press release
BRIDGEWATER, N.J., July 27, 2021 (GLOBE NEWSWIRE) -- Synchronoss Technologies, Inc. (NASDAQ: SNCR), a global leader and innovator of cloud, messaging and digital products and platforms, today announced the appointment of Christina “Chrissy” Gabrys as Chief Legal Officer. Gabrys succeeds Ronald Prague who is stepping down after 15 years with the company to pursue other interests. In her new role, Gabrys will oversee all legal affairs for the company. “Ron has played a significant role in shaping the Synchronoss that we are today. His leadership in negotiating and closing customer agreements, completing acquisitions and the company’s other financial endeavors – including his contribution to the successful recent recapitalization of the company – has been invaluable and he will be greatly missed,” said Jeff Miller, President and CEO of Synchronoss. “I would like to thank Ron for all he’s contributed to the business. We will always consider him part of the Synchronoss family and wish him w
SBM Offshore signs FPSO Almirante Tamandaré contracts27.7.2021 18:37:16 CEST | Press release
July 27, 2021 SBM Offshore is pleased to announce it has signed contracts with Petróleo Brasileiro S.A. (Petrobras) for the 26.25 years lease and operation of FPSO Almirante Tamandaré. These contracts follow the signing of the binding Letter of Intent as announced on February 25, 2021. FPSO Almirante Tamandaré will be deployed at the Búzios field in the Santos Basin approximately 180 kilometers offshore Rio de Janeiro in Brazil. SBM Offshore is progressing with the design and construction using its industry leading Fast4Ward® program. Delivery of the FPSO is expected in the second half of 2024. CorporateProfile The Company’s main activities are the design, supply, installation, operation and the life extension of floating production solutions for the offshore energy industry over the full lifecycle. The Company is market leading in leased floating production systems, with multiple units currently in operation. As of December 31, 2020, the Company employs approximately 4,570 people worl
Exel Industries :Third quarter 2020-2021 revenue : A sustained growth rate of 18.4%, in line with our expectations.27.7.2021 18:00:00 CEST | Press release
PRESS RELEASE July 27, 2021 Third quarter 2020-2021 revenue A sustained growth rate of 18.4%, in line with our expectations. Q3 revenue in €m2019 ‐ 20202020 - 2021Change in valueChange in %ReportedReportedReported* like‐for‐likeReported* like‐for‐likeAgricultural Spraying99.6113.814.216.414.3%16.4%Sugar Beet Harvesters222.214.171.1249.3%39.9%Garden Watering and Spraying50.149.8-0.3-0.8-0.6%-1.6%Industrial Spraying38.85516.217.941.9%46.2%EXEL Industries Group210.4249.238.842.218.4%20.1% *like‐for‐like = at constant foreign exchange rates and scope 9-month revenue in €m2019 - 20202020 - 2021Change in valueChange in %ReportedReportedReported* like‐for‐likeReported* like‐for‐likeAgricultural Spraying255.729236.342.114.2%16.5%Sugar Beet Harvesters53.863.81010.918.7%20.2%Garden Watering and Spraying89.3109.420.120.322.4%22.7%Industrial Spraying125.8169.243.43834.5%30.2%EXEL Industries Group524.7634.4109.8111.320.9%21.2% *like‐for‐like = at constant foreign exchange rates and scope Third quarte
Leasinvest Real Estate SA: Publication of a transparency notification27.7.2021 18:00:00 CEST | Press release
PUBLICATION OF A TRANSPARENCY NOTIFICATION IN ACCORDANCE WITH THE LAW OF 02/05/2007 ON THE DISCLOSURE OF IMPORTANT PARTICIPATIONS A notification of 27 July 2021 issued by AXA, shows a passive threshold overrun, following the introduction of the double voting rights and a capital increase by contribution in kind from a/o Extensa Group, as approved at the extraordinary general meeting of Leasinvest Real Estate on 19 July 2021. The total number of voting rights of AXA in Leasinvest Real Estate has decreased to 13.44% of the voting rights in Leasinvest Real Estate NV (hereinafter the "Company”). The notification comprises the following information: REASON FOR THE NOTIFICATION: Passive threshold overrun NOTIFICATION: by the parent company or controlling person. PERSON(S) SUBJECT TO THE NOTIFICATION REQUIREMENT Name and legal formAddress AXA SA 25, Avenue Matignon, 75008 Paris, France TRANSACTION DATE: 19 July 2021 THRESHOLD DROPPED BELOW: 15% DENOMINATOR: 11,804,919 DETAILS OF THE NOTIFICAT
ASM INTERNATIONAL N.V. REPORTS SECOND QUARTER 2021 RESULTS27.7.2021 18:00:00 CEST | Press release
Almere, The Netherlands July 27, 2021, 6 p.m. CET Continued robust market demand fuels strong quarterly performance ASM International N.V. (Euronext Amsterdam: ASM) today reports its second quarter 2021 operating results (unaudited) in accordance with IFRS. FINANCIAL HIGHLIGHTS EUR million Q2 2020 Q1 2021 Q2 2021 New orders 298.0 410.6 515.7 Revenue 341.8 394.0 411.7 Gross profit margin % 48.3 49.5 48.1 Operating result 87.6 124.5 118.4 Operating result margin % 25.6 31.6 28.7 Result from investments (excluding amortization intangible assets resulting from the sale of ASMPT stake in 2013) 10.7 13.9 19.3 Amortization intangible assets (resulting from the sale of ASMPT stake in 2013) (3.3) (3.0) (3.0) Net earnings 74.1 122.5 108.4 Normalized net earnings (excluding amortization intangible assets resulting from the sale of ASMPT stake in 2013 and result from sale of ASMPT shares) 77.4 125.5 111.4 New orders of €516 million for the second quarter 2021 increased by 73% compared to the same